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Abstract 
Background: Statin intolerance is often due to myalgias. Severe vitamin D deficiency is characterized by musculo‑
skeletal pain. We hypothesized that statin‑intolerance is associated with vitamin D deficiency.
Objectives: To determine whether there is an association between statin‑intolerance and vitamin D deficiency in a 
retrospective observational analysis.
Methods: We evaluated 20 female patients with prior myalgia‑related daily dose statin intolerance on an alternative 
day statin dosing protocol of twice weekly for 4 weeks followed by advancement to daily dosing, as tolerated. Fasting 
baseline and follow‑up lipid and 25‑hydroxy‑vitamin D (25‑OHD) levels were obtained by chart review.
Results: The group median age was 61 ± 13 years old and BMI was 27 ± 7 kg/m2. Women who remained on alterna‑
tive day statin dosing (n = 16) compared to women on daily dosing (n = 4) had a significantly lower group mean 
25‑OHD (mean 29 ± 11.23 vs. 47.5 ± 23.53 ng/ml p = 0.0307 respectively).
Conclusions: In women with prior myalgia‑related statin intolerance, vitamin D levels were significantly lower in 
women who remained on alternative day dosing compared to those who were tolerant of daily dosing.
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Background
Cardiovascular disease (CVD) is the single largest killer 
of women, [1] and more women than men die each year 
despite advancements in life-saving therapies [2]. In 
fact, patients with a total blood cholesterol level greater 
than 200 mg/dL have a two-fold risk of developing CVD. 
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors (statins) are currently the most 
effective treatment for lowering total cholesterol (TC), 
calculated low density lipoprotein (LDL-C), and reducing 
atherosclerotic cardiovascular risk (ASCVD) [3]. With a 
heightened focus on reducing ASCVD risk, statin com-
pliance is more important than ever in reducing cardio-
vascular events.
Compliance is often limited by myopathic pain symp-
toms. Approximately 1–2  % of patients will experience 
myalgias with statin therapy that can occur years after 
initiation of therapy [4]. In an earlier study, we demon-
strated that women who experience myalgias with statin 
use can be put on an alternate day statin dosing regimen 
that is effective in reducing TC and LDL-C and decreases 
the incidence of myalgias [5].
The pathophysiologic mechanisms hypothesized to 
play a role in the development of statin-induced myalgias 
include competition at the cytochrome P-450 (CYP3A4) 
enzyme [6], deficiency of mitochondrial enzyme CoQ [7, 
10] decreased plasma clearance in older patients [8], and/
or vitamin D deficiency [6]. Myalgias are defined as an 
unexplained muscle discomfort often described as “flu-
like symptoms in the setting of normal creatine kinase 
levels [9]. Patients may describe these symptoms as 
muscle aches, soreness, stiffness, muscle tenderness and 
cramps with exercise or immediately after exercise [9]. 
Myalgias are generally the first manifestation of vitamin 
D deficiency [6]. Due to the growing concern regarding 
the prevalence and significance of vitamin D deficiency 
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[10, 11], we hypothesized that women who are unable to 
tolerate daily dosing statin therapy have lower vitamin D 
levels than those who are able to tolerate daily dosing.
Methods
We conducted a retrospective clinical chart review on 
20 female patients from a tertiary chest pain center in 
2008–2013. All women had an indication to be on sta-
tin therapy and had developed statin-induced myalgias. 
None of the women had a prior history of muscle related 
myalgias prior to statin therapy. According to clinical 
care practice, women with statin-induced myalgias were 
switched to a different statin and placed on an alterna-
tive day statin dosing regimen (simvastatin, atorvastatin, 
pravastatin, rosuvastatin, fluvastatin XL, or pitavastatin). 
Patients started low to moderate-intensity [3] statin ther-
apy twice weekly, Mondays and Thursdays regimen for 
4 weeks, and then titrated up 1 day per week as tolerated 
until either daily dosing was achieved or the patient expe-
rienced their prior myalgia pain. In that case, the patient 
was taken back to the previous tolerated alternative day 
dosing regimen (Fig. 1). Alternative day statin dosing was 
defined as any regimen less than daily. Patients included 
in the study were those with documented history of being 
placed on an alternative day statin dosing regimen with 
a corresponding vitamin D level drawn within 3 months 
of clinic visit. Laboratory data regarding vitamin D lev-
els, creatinine kinase, hepatic transaminases, and fasting 
lipid panel were collected from chart review. Information 
regarding prior failed statin history, supplement use, car-
diac risk factors, and demographic data was all obtained 
from chart review, which was approved by the Institu-
tional Review Board at Cedars-Sinai Medical Center. 
Data were analyzed using a t test.
Ethical aspects
This study conforms to the principles outlined in the 
Declaration of Helsinki and was approved by the Cedars-
Sinai Institutional Review Board in Los Angeles, Cali-
fornia, United States (Pro00023187). The study was 
registered at ClinicalTrials.gov (NCT01568255).
Results
The study group mean age was 61  ±  13  years old and 
the mean body mass index (BMI) was 27  ±  7  kg/m2. 
The majority of women were Caucasian (17 women) and 
the remainder were African American (3 women). All 
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Fig. 1 Prescribed dosing of statins used
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regards to additional CVD risk factors, 11 women had 
hypertension, 10 women had a significant family his-
tory of premature coronary artery disease (CAD), and 6 
women had known CAD, 10 women had a previous or 
active smoking history and none had diabetes. Women 
were further subdivided demographically as either alter-
native day statin dosing (n = 16) or daily dosing (n = 4) 
(Table  1). Only 5 women were taking non-prescription 
strength over-the-counter vitamin D supplements 1000–
2000 IU at the time data was collected regarding vitamin 
D level and statin-induced myalgias.
Of the 20 women in the study, 16 (76 %) remained on 
alternative day statin dosing due to myalgias. On aver-
age, women had intolerance to at least 2 previous statins 
before finding a regimen that left them pain free. Wil-
coxon rank sum tests between dosing groups showed 
no significant differences in total cholesterol on sta-
tin daily statin dosing vs. alternative day statin dosing 
(p = 0.5712), or LDL on daily statin dosing vs. alternative 
day statin dosing (p = 0.4367).
Overall, the mean 25-OHD level for the total group 
was 32.78  ±  15.62. Women who remained on alterna-
tive day statin dosing (n =  16) compared to women on 
daily dosing (n = 4) had a significantly lower group mean 
25-OHD (mean 29.09 ±  11.23 vs. 47.5 ±  23.53  ng/ml t 
test p = 0.0307 respectively) (Fig. 2).
Discussion
We report that women with statin myalgias and unable 
to tolerate daily statin dosing had significantly lower 
vitamin D levels compared to women who were able to 
achieve daily statin dosing. This pilot, cross-sectional, 
retrospective study supports previous anecdotal obser-
vations that vitamin D deficiency may be associated with 
statin-induced myalgias.
A systematic review and meta-analysis by Michalska-
Kasiczak et  al. supports our findings [11]. Their com-
pilation of 2420 statin treated patients observed that 
vitamin D plasma concentrations were significantly lower 
in patients with statin-associated myalgias compared to 
those not experiencing myalgias [11]. Three published 
papers have previously suggested a positive association 
between vitamin D deficiency and statin-induced myal-
gias [6, 12, 13]. One clinical study conducted by Ahmed 
et  al. [13] studied this association by treating vitamin 
D deficient patients with statin-induced myalgias with 
50,000 IU of ergocalciferol. Overall, 92 % of patients had 
resolution of myalgia symptoms after repletion of vita-
min D levels when challenged with the same statin used 
at study entry. However, the lack of a control arm pre-
vents differentiation between a true therapeutic role of 
ergocalciferol versus a placebo effect.
The questionable relationship between vitamin D defi-
ciency and statin-induced myalgias was brought under 
scrutiny in a Letter to the Editor published in the April 
2011 issue of Atherosclerosis [14]. Backes et  al. com-
pared vitamin D levels of a group of 72 patients intolerant 
to a median of 3 different statin medications to a group 
of 57 patients with no previous history of statin intoler-
ance and found no difference between groups [14]. While 
these findings are inconsistent with ours, this may be 
because our entire study population of 20 women had 
failed an average of 2 statins. We made comparisons of 
vitamin D levels within this group of intolerant patients, 
unlike Backes et al. who compared the group of intoler-
ant statin users to patients who had never experienced 
myalgias.
There are several hypotheses to explain this relation-
ship between vitamin D deficiency and statin-induced 
myalgias. As a patient becomes deficient in vitamin D 
they may develop osteomalaci myopathy. Low vitamin D 
stores in these patients are associated with increased body 
sway, decreased muscular strength, changes in gait, diffi-
culties in rising from a chair, inability to ascend stairs and 
diffuse muscle pain [15, 16]. These symptoms of muscu-
loskeletal pain appear to be similar in nature to the mus-
cle pain, or myalgias, associated with statin use [13]. An 
Table 1 Demographic data





Alternate day  
dosing (n = 16)
P value*
Age (years ± SD) 61.8 ± 17.5 60.4 ± 11.8 0.9245
Hypertensive 50 % 56.3 % 1
CAD 25 % 35.7 % 1
Diabetes mellitus 0 0 –
History of smoking 100 % 40 % 0.0867
Fig. 2 Vitamin D levels in alternative dosing vs. daily dosing in 
patients with statin‑related myalgias
Page 4 of 5Minissian et al. BMC Res Notes  (2015) 8:449 
alternate theory involves competition of the CYP3A4 
isozyme that is both responsible for statin metabolism 
and vitamin D activation. It is theorized that in vitamin 
D deficient states, CYP3A4 preferentially hydroxylates 
25-OHD instead of metabolizing statins, leading to statin-
induced toxicity which may result in myalgias [4, 6, 7]. 
Statins that most commonly cause myalgias (simvastatin 
and atorvastatin) inhibit the CYP 3A4 system. Finally, 
age-related changes may be playing a role in the associa-
tion of vitamin D deficiency and myalgias in the setting 
of statin use. It is well established that increasing age is 
a risk factor for developing statin-induced myalgias [3]. 
Early in vitro studies have shown that vitamin D receptors 
(VDR) on muscle cells have been shown to decrease with 
age [15, 16, 17]. Because our study population has a mean 
age of 60 ± 13 years of age, it may be that the women we 
observed have fewer VDR’s per muscle cell which may 
lead to decreased nuclear receptor activation causing 
poor muscle strength and/or function [15, 16–17].
Limitations
Because our pilot study was a cross-sectional, retrospec-
tive study, conclusions regarding definitive linkage and 
causality cannot be drawn. Patients were not on a stand-
ardized statin regimen; therefore, it may be that a certain 
statin did not interact with vitamin D pathways result-
ing in the absence of myalgias. Furthermore, due to the 
small sample size, individual statins could not be assessed 
against vitamin D to identify independent associations; 
however, even with the small sample size, a statistically 
significant relationship was seen between two groups. 
There was a wide range in vitamin D levels and smaller 
numbers of women, the influence of the highest sample 
is larger and could have possibly affected the significance. 
We have taken this into consideration and have designed 
a larger, prospective, randomized, double blind study of 
50,000 IU of ergocalciferol versus placebo.
Conclusions
Our study findings support earlier suggestions of a posi-
tive association between vitamin D deficiency and statin-
induced myalgias. More work needs to be done to define 
this relationship and uncover the mechanistic pathway 
for the relationship observed. To that end, we are con-
ducting a randomized, double blinded placebo controlled 
interventional trial to test the hypothesis that vitamin D 
supplementation improves statin tolerance in subjects 
with vitamin D deficiency.
Abbreviations
BMI: body mass index; CVD: cardiovascular disease; CAD: coronary artery dis‑
ease; CYP3A4: cytochrome P‑450; 25‑OHD: 25 hydroxyvitamin D; VDR: vitamin 
D receptor.
Authors’ contributions
MM and CNBM are co‑principal investigators, MW, MA, CS, PM, NBM designed 
the study. MM, MA, TW drafted the manuscript. JE, PM, NBM revised the 
manuscript critically. GL conducted the statistical analysis of the manuscript. 
All authors read and approved the final manuscript.
Acknowledgements
We would like to thank the staff and management at the Barbra Streisand 
Women’s Heart Center.
This work was supported by the National Lipid Foundation, contracts 
from the National Heart, Lung and Blood Institutes nos. N01‑HV‑68161, 
N01‑HV‑68162, N01‑HV‑68163, N01‑HV‑68164, grants U0164829, U01 
HL649141, U01 HL649241, K23HL105787, T32HL69751, R01 HL090957, 
1R03AG032631 from the National Institute on Aging, GCRC grant MO1‑
RR00425 from the National Center for Research Resources, the National Center 
for Advancing Translational Sciences Grant UL1TR000124 and UL1TR000064, 
and grants from the Gustavus and Louis Pfeiffer Research Foundation, 
Danville, NJ, The Women’s Guild of Cedars‑Sinai Medical Center, Los Angeles, 
CA, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA, 
and QMED, Inc., Laurence Harbor, NJ, the Edythe L. Broad and the Constance 
Austin Women’s Heart Research Fellowships, Cedars‑Sinai Medical Center, Los 
Angeles, California, the Barbra Streisand Women’s Cardiovascular Research 
and Education Program, Cedars‑Sinai Medical Center, Los Angeles, The Society 
for Women’s Health Research (SWHR), Washington, D.C., The Linda Joy Pollin 
Women’s Heart Health Program, and the Erika Glazer Women’s Heart Health 
Project, Cedars‑Sinai Medical Center, Los Angeles, California.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 24 January 2014   Accepted: 17 August 2015
References
 1. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada‑Vera B. Deaths: 
final data for 2006. National vital statistics reports: from the Centers for 
Disease Control and Prevention, National Center for Health Statistics, 
National Vital Statistics System. 2009;57(14):1–134.
 2. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness‑based guidelines for 
the prevention of cardiovascular disease in women—2011 update: 
a guideline from the American Heart Association. J Am Coll Cardiol. 
2011;57(12):1404–23.
 3. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on 
the treatment of blood cholesterol to reduce atherosclerotic cardiovas‑
cular risk in adults: a report of the American College of Cardiology/Ameri‑
can Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2013.
 4. Thompson PD, Clarkson P, Karas RH. Statin‑associated myopathy. JAMA. 
2003;289(13):1681–90.
 5. Minissian MKK, Frida P, Shufelt C, Agarwal M, Mehta P, Eastwood J, Yang 
Y, Bairey Merz CN. Alternative statin protocol: a novel nurse practitioner 
managed approach for treating women with previous statin intolerance. 
Chicago: American Heart Association Scientific Sessions; 2010.
 6. Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency–a novel mecha‑
nism of statin‑induced myalgia? Clin Endocrinol (Oxf ). 2009;71(1):154–5.
 7. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin‑associated 
myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7.
 8. Pasternak RC, Smith SC Jr, Bairey‑Merz CN, Grundy SM, Cleeman JI, Len‑
fant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. 
Circulation. 2002;106(8):1024–8.
 9. Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The 
national lipid association’s muscle safety expert P. An assessment by 
the statin muscle safety task force: 2014 update. J Clin Lipidol. 2014;8(3 
Suppl):S58–71.
Page 5 of 5Minissian et al. BMC Res Notes  (2015) 8:449 
 10. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.
 11. Michalska‑Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin 
D levels in patients with and without statin‑associated myalgia—a 
systematic review and meta‑analysis of 7 studies with 2420 patients. Int J 
Cardiol. 2015;178:111–6.
 12. Lee JH, O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency: 
an important, common, and easily treatable cardiovascular risk factor? J 
Am Coll Cardiol. 2008;52(24):1949–56.
 13. Ahmed W, Khan N, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels 
(<32 ng/mL) are associated with reversible myositis‑myalgia in statin‑
treated patients. Transl Res. 2009;153(1):11–6.
 14. Backes JM, Barnes BJ, Ruisinger JF, Moriarty PM. A comparison of 
25‑hydroxyvitamin D serum levels among those with or without statin‑
associated myalgias. Atherosclerosis. 2011;218(1):247–9.
 15. Badsha H, Daher M, Ooi Kong K. Myalgias or non‑specific muscle pain in 
Arab or Indo‑Pakistani patients may indicate vitamin D deficiency. Clin 
Rheumatol. 2009;28(8):971–3.
 16. Pfeifer M, Begerow B, Minne H. Vitamin D and muscle function. Osteo‑
poros Int. 2002;13(3):187–94.
 17. Bischoff‑Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25‑hydroxyvitamin 
D concentrations are associated with better lower‑extremity function 
in both active and inactive persons aged > or = 60 y. Am J Clin Nutr. 
2004;80(3):752–8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
